Targeted Therapies in Low-Grade Serous Ovarian Cancers

Anna Gonzalez; Christa I. Nagel; Paulina J. Haight

doi:10.1007/s11864-024-01205-4

Targeted Therapies in Low-Grade Serous Ovarian Cancers

Anna Gonzalez, Christa I. Nagel, Paulina J. Haight

Obstetrics & Gynecology

Research output: Contribution to journal › Article › peer-review

Abstract

Low grade serous carcinoma of the ovary has been delineated as a separate entity from its counterpart high grade serous carcinoma of the ovary. Molecular profiling has helped to further characterize this disease process and has led to new and exciting treatment options. Surgery has always been a cornerstone of management both in primary and recurrent disease settings. Chemotherapy has been a long-standing backbone of adjuvant treatment, but its efficacy continues to be questioned. Hormonal therapy for upfront and recurrent disease is an effective treatment option with a high response rate and minimal side effects. Newer therapies including MEK, CDK 4/6, and PI3KCA inhibitors have emerged as exciting options for recurrent disease. Ongoing clinical trials will hopefully lead to additional therapeutic opportunities based on novel biomarkers in this disease.

Original language	English
Pages (from-to)	854-868
Number of pages	15
Journal	Current Treatment Options in Oncology
Volume	25
Issue number	7
DOIs	https://doi.org/10.1007/s11864-024-01205-4
State	Published - Jul 2024

Keywords

Low-grade serous ovarian cancer

Access to Document

10.1007/s11864-024-01205-4

Cite this

@article{77d7334396cc4a80b224d9a7ed6c96ee,

title = "Targeted Therapies in Low-Grade Serous Ovarian Cancers",

abstract = "Low grade serous carcinoma of the ovary has been delineated as a separate entity from its counterpart high grade serous carcinoma of the ovary. Molecular profiling has helped to further characterize this disease process and has led to new and exciting treatment options. Surgery has always been a cornerstone of management both in primary and recurrent disease settings. Chemotherapy has been a long-standing backbone of adjuvant treatment, but its efficacy continues to be questioned. Hormonal therapy for upfront and recurrent disease is an effective treatment option with a high response rate and minimal side effects. Newer therapies including MEK, CDK 4/6, and PI3KCA inhibitors have emerged as exciting options for recurrent disease. Ongoing clinical trials will hopefully lead to additional therapeutic opportunities based on novel biomarkers in this disease.",

keywords = "Low-grade serous ovarian cancer",

author = "Anna Gonzalez and Nagel, {Christa I.} and Haight, {Paulina J.}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = jul,

doi = "10.1007/s11864-024-01205-4",

language = "English",

volume = "25",

pages = "854--868",

journal = "Current Treatment Options in Oncology",

issn = "1527-2729",

number = "7",

}

TY - JOUR

T1 - Targeted Therapies in Low-Grade Serous Ovarian Cancers

AU - Gonzalez, Anna

AU - Nagel, Christa I.

AU - Haight, Paulina J.

N1 - Publisher Copyright: © The Author(s) 2024.

PY - 2024/7

Y1 - 2024/7

N2 - Low grade serous carcinoma of the ovary has been delineated as a separate entity from its counterpart high grade serous carcinoma of the ovary. Molecular profiling has helped to further characterize this disease process and has led to new and exciting treatment options. Surgery has always been a cornerstone of management both in primary and recurrent disease settings. Chemotherapy has been a long-standing backbone of adjuvant treatment, but its efficacy continues to be questioned. Hormonal therapy for upfront and recurrent disease is an effective treatment option with a high response rate and minimal side effects. Newer therapies including MEK, CDK 4/6, and PI3KCA inhibitors have emerged as exciting options for recurrent disease. Ongoing clinical trials will hopefully lead to additional therapeutic opportunities based on novel biomarkers in this disease.

AB - Low grade serous carcinoma of the ovary has been delineated as a separate entity from its counterpart high grade serous carcinoma of the ovary. Molecular profiling has helped to further characterize this disease process and has led to new and exciting treatment options. Surgery has always been a cornerstone of management both in primary and recurrent disease settings. Chemotherapy has been a long-standing backbone of adjuvant treatment, but its efficacy continues to be questioned. Hormonal therapy for upfront and recurrent disease is an effective treatment option with a high response rate and minimal side effects. Newer therapies including MEK, CDK 4/6, and PI3KCA inhibitors have emerged as exciting options for recurrent disease. Ongoing clinical trials will hopefully lead to additional therapeutic opportunities based on novel biomarkers in this disease.

KW - Low-grade serous ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=85196075318&partnerID=8YFLogxK

U2 - 10.1007/s11864-024-01205-4

DO - 10.1007/s11864-024-01205-4

M3 - Article

C2 - 38869696

AN - SCOPUS:85196075318

SN - 1527-2729

VL - 25

SP - 854

EP - 868

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

IS - 7

ER -

Targeted Therapies in Low-Grade Serous Ovarian Cancers

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this